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Early inflammatory response after elective
abdominal aortic aneurysm repair: A
comparison between endovascular
procedure and conventional surgery
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Objective: To determine the nature of and to compare the inflammatory responses induced
by (1) endovascular and (2) conventional abdominal aortic aneurysm (AAA) repair.
Material and methods: Twelve consecutive patients undergoing elective infrarenal AAA
repair were prospectively studied. Seven patients were selected for endovascular proce-
dures (the EAAA group); five patients underwent open surgery (the OAAA group).
Three control patients undergoing carotid thromboendarterectomy were also included.
Serial peripheral venous blood samples were collected preoperatively, immediately after
declamping or placement of the endograft, and at hours 1, 3, 6, 12, 24, 48, and 72.
Acute phase response expression of peripheral T lymphocyte and monocyte activation
markers and adhesion molecules (flow cytometry), soluble levels of cell adhesion mole-
cules (enzyme-linked immunosorbent assay), cytokine (tumor necrosis factor α, inter-
leukin-6, and interleukin-8) release (enzyme-linked immunosorbent assay), and libera-
tion of complement products (nephelometry) were measured.
Results: Regarding acute phase response, the EAAA and OAAA groups showed signifi-
cant increases in C-reactive protein (P < .001 and P = .001), body temperature (P = .035
and P = .048), and leukocyte count (P < .001 and P < .001). Similar time course pat-
terns were observed with respect to body temperature (P = .372). Statistically significant
different patterns were demonstrated for C-reactive protein (P = .032) and leukocyte
count (P = .002). Regarding leukocyte activation, a significant upregulation of periph-
eral T lymphocyte CD38 expression was observed in the OAAA group only (P = .001).
Analysis of markers such as CD69, CD40L, CD25, and CD54 revealed no perioperative
fluctuations in any group. Regarding circulating cell adhesion molecules, the EAAA and
OAAA groups displayed significant increases in soluble intercellular adhesion molecule-
1 (P = .003 and P = .001); there was no intergroup difference (P = .193). All groups
demonstrated high soluble von Willebrand factor levels (P = .018, P = .007, and P =
.027), there being no differences in the patterns (P = .772). Otherwise, soluble vascular
cell adhesion molecule-1, soluble E-selectin, and soluble P-selectin did not appear to
vary in any group. Regarding cytokine release, although a tendency toward high tumor
necrosis factor α and interleukin-8 levels was noticed in the EAAA group, global time
course effects failed to reach statistical significance (P = .543 and P = .080). In contrast,
interleukin-6 showed elevations in all groups (P = .058, P < .001, and P = .004). Time
course patterns did not differ between the EAAA and OAAA groups (P = .840).
Regarding complement activation, the C3d/C3 ratio disclosed significant postoperative
elevations in the EAAA and OAAA groups (P = .013 and P = .009). This complement
product release was reduced in the EAAA group (P < .001). 
From the Department of Vascular Diseases,a Department of
Haematology-Immunology,b and IRIBHN Statistical Unit,c
Hôpital Erasme, Université Libre de Bruxelles.
Competition of interest: nil.
Supported in part by a research grant from Fondation Erasme,
Brussels, Belgium.
Reprint requests: C. Galle, MD, Department of Vascular
Diseases, Hôpital Erasme, Route de Lennik, 808, B-1070
Brussels, Belgium.
Copyright © 2000 by The Society for Vascular Surgery and  The
American Association for Vascular Surgery, a Chapter of the
International Society for Cardiovascular Surgery.
0741-5214/2000/$12.00 + 0 24/1/107562
doi:10.1067/mva.2000.107562
Abdominal aortic aneurysm (AAA) is a frequent
disease, with a reported incidence of 3.0 to 117.2
per 100,000 persons per year.1,2 Standard manage-
ment of the condition consists of prosthetic graft
interposition requiring open laparotomy, bowel
manipulation, and aortic cross-clamping. This
approach is associated with an overall mortality rate
of approximately 5%,1 although severe comorbidi-
ties, particularly among older patients, may increase
the surgical risk. A significant proportion of the
adverse events are linked to the occurrence of 
cardiac events, pulmonary dysfunction, or renal
impairment, often leading to acute respiratory dis-
tress syndrome or multiple organ failure. These inci-
dents result from the development of an extensive
and uncontrolled inflammatory response in which
recruitment and migration of activated leukocytes
(mainly neutrophils), controlled and modulated by
proinflammatory mediators (cytokines) and chemo-
tactic factors (chemokines and complement pro-
teins), are thought to play a pivotal role.3-5 This cas-
cade of events has been attributed both to tissue
damage and ischemia-reperfusion injury related to
aortic clamping3-7 and to local cellular interactions
arising at the blood/biomaterial interface.8-10
Endovascular procedures have recently been pro-
posed as minimally invasive alternative treatments11-14
allowing safe and effective AAA repair.15-18 The
method is believed to offer several advantages over
open surgery in terms of reduced mortality and mor-
bidity rates18-20 and restricted perioperative hemody-
namic parameter fluctuations.21-23 Several studies
have also demonstrated that this approach led to a less
intense and extensive inflammatory response, espe-
cially as regards cytokine release,24,25 thereby assess-
ing the concept of limited tissue damage, ischemia-
reperfusion insult, and subsequent inflammatory
events after endovascular repair. In contrast, recent
reports have mentioned that endoluminal procedures
may elicit an unexpected systemic inflammatory
response,12,26-28 which has been named postimplan-
tation syndrome.12 Indeed, observations from
Swartbol et al26,28 and Norgren et al27 have provided
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arguments in favor of a specific, exclusively endovas-
cular-related tumor necrosis factor α (TNFα)
response associated with a clinically relevant fall in sys-
tolic blood pressure. The authors made the assump-
tion26-28 that manipulations with introducers and
catheters into the aortic aneurysm and its intramural
thrombus might trigger the liberation of cytokines,
causing activation of white blood cells (WBCs), which
are, in turn, able to promote TNFα release. The same
research team recently produced evidence for this
hypothesis by identification of high interleukin-6 (IL-
6) amounts in AAA thrombotic contents,29 this being
parallel to the demonstration that AAA intramural
thrombus supernatants were able to initiate WBC
production of TNFα.29
These conflicting data prompted us to explore
early acute systemic inflammatory responses occurring
in a nonrandomized cohort of patients undergoing
elective endovascular or conventional infrarenal AAA
repair. The aim of our study was to determine the
nature of and compare the inflammatory responses
induced by endovascular1 and conventional2 AAA
repair. The study was designed to concomitantly
examine acute phase response (C-reactive protein
[CRP], body temperature, and leukocyte and 
neutrophil counts) and several pathways of the inflam-
matory cascade: expression of peripheral T lympho-
cyte and monocyte activation markers, circulating lev-
els of cell adhesion molecules, cytokine (TNFα and
IL-6) and chemokine (interleukin-8 [IL-8]) release,
and liberation of complement proteins.
MATERIAL AND METHODS
Patients
Twelve consecutive patients undergoing elective
repair of infrarenal AAA were included in the study.
Of these, seven patients (all men aged 65-81 years)
were selected for insertion of aortoiliac grafts
through use of endoluminal procedures (the EAAA
group); the other five patients (all men aged 62-71
years) underwent open surgery (the OAAA group).
Selection for the EAAA group was based on 
Conclusions: The current study indicated that both endovascular and coventional AAA
repair induced significant inflammatory responses. Our findings showed that there were
no large differences between the procedures with respect to circulating cell adhesion
molecule and cytokine release. Moreover, the endoluminal approach produced a limited
response in terms of acute phase reaction, T lymphocyte activation, and complement
product liberation. This might support the concept that endovascular AAA repair rep-
resents an attractive alternative to open surgery. Given the relatively small sample size,
further larger studies are required for confirmation of our observations. (J Vasc Surg
2000;32:234-46.)
radiographic criteria established with angiography and
computed tomography to ascertain that the aneurysm
morphologic features were suitable for the endolumi-
nal procedure. As previously suggested,11,30 these
characteristics were defined as a proximal neck at least
15 mm in length, a proximal aortic diameter less than
26 mm, and common iliac and femoral arteries
demonstrating limited tortuosity and showing suffi-
cient caliber to allow passage of the introducer sheath.
Exclusion criteria included diabetes mellitus,
neoplasia, hepatic dysfunction, renal failure, infec-
tious or inflammatory diseases, and thrombotic dis-
orders. Patients taking corticosteroids and/or
immunosuppressive drugs were also excluded.
Three additional patients (all men aged 65-74
years) undergoing carotid thromboendarterectomy
were included as a control group to determine the
specificity of the inflammatory events observed rela-
tive to AAA repair.
Demographic data for the cohort patients are
presented in Table I. The study protocol was
approved by the local Medical Ethical Committee.
All patients gave informed written consent.
Surgical procedure
Both conventional and endovascular procedures
were performed after the induction of general anes-
thesia. Endovascular repair was performed through
use of the Corvita Endoluminal Graft System
(Corvita Corporation, Miami, Fla), as previously
described.31 Briefly, this modular system consists of
a self-expanding stent of braided wires internally
covered by a liner of polycarbonate-urethane fibers
(Corethane), and it includes a bifurcated aortic tube
27 mm in diameter as well as two aortoiliac exten-
sion legs each 14 mm in diameter. During the pro-
cedure, endografts were delivered through common
femoral arteries, which were occluded for a short
period, allowing introduction of the delivery system
and endograft insertion.
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Fig 1. A, Time course of CRP and body temperature measured as mg/dL and degrees Celsius, respec-
tively (nonlinear time scale). Each result is expressed as mean (SEM). Continuous lines between time
points represent EAAA group, dotted lines represent OAAA group, and broken lines represent control
group. P values after within-group tests comparing each time point with baseline (preoperative) value
are represented as follows: *P < .05, **P < .01, ***P < .001. B, Time course of leukocyte and neu-
trophil counts measured as 103/mm3 (nonlinear time scale). Each result is expressed as mean (SEM).
Continuous lines between time points represent EAAA group, dotted lines represent OAAA group, and
broken lines represent control group. P values after within-group tests comparing each time point with
baseline (preoperative) value are represented as follows: *P < .05, **P < .01, ***P < .001.
A B
Conventional repair was undertaken according
to a standard transperitoneal approach that involved
the use of transverse laparotomy and aortic cross-
clamping below the renal arteries. In this group,
three bifurcated and two tube-knitted collagen-coat-
ed Dacron grafts (Intergard, Intervascular, La
Ciotat, France) were placed.
Each patient received 10,000 IU of heparin
intravenously before clamping or insertion of the
endograft. At the end of the procedure, the heparin
was reversed by means of 100 mg of intravenous
protamine. Clinical information on operation time,
clamping time, blood loss, blood transfusion, infu-
sions, and body temperature, as well as details on
postoperative complications (infectious or throm-
boembolic events, proximal or distal perigraft leaks,
endograft migration, and graft thrombosis or infec-
tion) and clinical outcomes (throughout a 6-month
follow-up period) were recorded.
Blood collection
In each patient, serial peripheral venous blood
samples were collected as follows: preoperatively on
the day of surgery (hour –1); immediately after
declamping or placement of the endograft (hour 0);
and at hours 1, 3, 6, 12, 24, 48, and 72 after clamp
removal or placement of the endograft. Blood sam-
ples were obtained by means of careful venipuncture,
performed in all cases by the same investigator 
(C. G.). After the first 5 mL was discarded, blood was
drawn into sterile 4.5-mL tubes, each containing 0.5
mL of buffered saline sodium citrate (Terumo
Venoject, Terumo Europe N.V., Leuven, Belgium),
and immediately stored at 4˚C until assayed. Assays
were carried out within 2 hours of sample collection;
whole blood samples were immediately processed for
flow cytometric analysis, whereas plasma samples
obtained by centrifugation were aliquoted and stored
at –80˚C until further analysis.
Laboratory techniques
Measurement of blood cell count and CRP.
WBC counts with cell differentiation and hemoglo-
bin concentrations were determined with an auto-
mated cell counter (CELL-Dyn 3500, Abbott
Diagnostics Division, Mountain View, Calif).
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Table I. Patient demographic characteristics
AAA repair
Endovascular (n = 7) Conventional (n = 5) Carotid TEA (n = 3) P value
Age* (y) 73.0 (2.33) 66.2 (1.83) 70.3 (2.73) .134
Sex (M/F) 7/0 5/0 3/0 —
Clinical history
Hypertension 3 2 2 —
Hypercholesterolemia 4 3 3 —
Coronary disease 2 1 1 —
Chronic pulmonary disease 5 5 3 —
Cerebrovascular disease 1 0 0 —
Smoking habits: current smoker 5 5 3 —
*Mean (SEM).
TEA, Thromboendarterectomy.
Table II. Operative details
AAA repair 
Endovascular (n = 7) Conventional (n = 5) P value
Aneurysm diameter* (mm) 56.57 (3.87) 56.40 (5.95) .980
Intramural thrombus 7 5 —
Surgical data
Duration of surgery* (min) 112.86 (5.33) 178.00 (24.42) .012
Aortic or femoral occlusion time* (min) 16.81 (1.29) 60.00 (8.22) < .001
Blood loss* (mL) 21.43 (21.43) 1700.00 (630.08) .056
Transfusion volume*† (mL) 0.00 (0.00) 1370.00 (389.74) .025
Infusion volume* (mL) 1714.29 (148.69) 4900.00 (244.95) < .001
Drop in SBP after declamping* (mm Hg) 0.71 (0.71) 26.60 (5.88) .011
*Mean (SEM).
†Cell-saver and red blood cell transfusions.
SBP, Systolic blood pressure.
Hemoglobin values were used for correction of
hemodilution effects on cell counts. CRP levels were
determined according to a turbidimetric method
involving the use of a TINA-Quant CRP Kit
(Boehringer, Heidelberg, Germany). Results are
expressed as mg/dL. Normal values are below 0.5
mg/dL.
Measurement of the surface expression of
peripheral leukocyte activation markers and
adhesion molecules 
Monoclonal antibodies. Three-color staining of
peripheral T lymphocytes was performed through
use of fluorescein isothiocyanate–conjugated mouse
immunoglobulin G1 (IgG1) CD69 or CD25 (anti-
IL-2R), R-phycoerythrin–conjugated mouse IgG1
CD154 (anti-CD40L) or CD38, and PerCP-conju-
gated mouse IgG1 CD3 monoclonal antibodies
(MoAbs; Becton Dickinson, San Jose, Calif).
Staining of peripheral monocytes was performed
through use of R-phycoerythrin–conjugated mouse
IgG1 CD54 (ICAM-1) MoAb (Becton Dickinson)
and PE-Cy5–conjugated mouse IgG2a CD14
MoAb (Bioproducts, Boehringer, Heidelberg,
Germany). Cells were processed through use of iso-
type mouse IgG1-matched and IgG2a-matched
MoAbs (Becton Dickinson) and served as negative
controls to quantify nonspecific staining.
Cell staining. We prepared each sample for flow
cytometry by immediately adding 100 µL of citrated
whole blood to 5 µL of each MoAb in a polypropy-
lene particle-free tube (Sarstedt, Essen, Germany);
the sample was mixed thoroughly and then incubat-
ed for 15 minutes at 4˚C in the dark. After the stain-
ing, erythrocytes were lysed by the addition of 2 mL
of NH4Cl solution for 10 minutes. The cells were
then centrifuged at 1800 rpm for 10 minutes and
washed in phosphate-buffered saline solution (Bio
Whittaker, Verviers, Belgium). After removal of the
supernatant, cells were finally suspended in 400 µL of
phosphate-buffered saline–paraformaldehyde 1%
(Merck, Darmstadt, Germany) solution and stored at
4˚C until later analysis.
Flow cytometry. Flow cytometric analysis was per-
formed within 24 hours of sample staining on a
FACScan Flow Cytometer (Becton Dickinson);
CELLQuest software (Becton Dickinson) was used
for data acquisition and analysis. Fluorescence chan-
nels were set at logarithmic gain. Lymphocytes were
gated according to their forward versus side light-
scatter properties. The T cell subpopulation was then
identified by gating on the CD3 positive events. The
monocyte population was defined according to its
forward versus side light-scatter region, combined
with gating on the CD14 positive cells. A minimum
of 5000 events were collected, and the median chan-
nel fluorescence (MCF) intensity of the stained cells
was recorded.
Measurement of soluble adhesion molecules.
Plasma-soluble E-selectin (sE-selectin), P-selectin
(sP-selectin), vascular cell adhesion molecule-1
(sVCAM-1), and intercellular adhesion molecule-1
(sICAM-1) levels were measured through use of
commercially available enzyme-linked immunosor-
bent assays (ELISAs; R&D Systems, Abingdon,
United Kingdom), according to the manufacturer’s
instructions. The optical densities were spectropho-
tometrically determined at 450 nm (reference filter,
620 nm) through use of a microplate ELISA 
autoreader (Bio-Tek Instruments, Winooski, Vt).
The optical densities of the standard solutions were
then plotted through use of KinetiCalc Analyser soft-
ware (Bio-Tek Instruments), and adhesion molecule
concentrations (in ng/mL) of the test samples were
obtained from the standard curve. Hemoglobin con-
centrations were used for the correction of hemodi-
lution effects. The sensitivities of the assays were
given as 0.1, 0.5, 2.0, and 0.3 ng/mL, for sE-
selectin, sP-selectin, sVCAM-1, and sICAM-1,
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Table III. Lymphocyte, monocyte, and eosinophil counts
AAA repair
Endovascular (n = 7) Conventional (n = 5)
Preop value Postop lowest value Preop value Postop lowest value
Lymphocyte (103/mm3) 1.77 (0.28) 1.25 (0.19)* 1.45 (0.24) 0.47 (0.02)†
Monocyte (103/mm3) 0.66 (0.06) 0.45 (0.10)* 0.50 (0.07) 0.25 (0.07)†
Eosinophil (103/mm3) 0.16 (0.04) 0.07 (0.01)* 0.09 (0.03) 0.005 (0.001)*
Each variable is expressed as mean value (SEM).
P values after within-group tests comparing lowest postoperative value with baseline (preoperative) value are represented as follows: 
*P <.05, †P < .01.
Preop, Preoperative; Postop, postoperative; E, endovascular procedure; O, open surgery.
respectively. Normal values are 46.3 (range, 29.1-
63.4), 190 (range, 111-266), 553 (range, 395-714),
and 230.3 (range, 129.9-297.4) ng/mL for sE-
selectin, sP-selectin, sVCAM-1, and sICAM-1,
respectively.
Measurement of von Willebrand factor.
Levels of von Willebrand factor (vWF) were 
measured on an automated VIDAS Analyser (Vitek
Systems, Biomérieux, Marcy-l’Etoile, France)
through use of an enzyme immunoassay method
(Vidas vWF, Biomérieux), according to the manu-
facturer’s instructions. Hemoglobin concentrations
were used for correction of hemodilution effects.
Results are expressed as percents. The sensitivity of
the assay was given as below 1%. Normal values are
52% to 154%.
Measurement of cytokines. Plasma levels of sol-
uble TNFα, IL-6, and IL-8 were quantified through
use of enzyme-amplified sensitivity immunoassays
(Medgenix EASIA Kit, Biosource Europe, Fleurus,
Belgium), according to the manufacturer’s instruc-
tions. The optical densities were spectrophotometri-
cally determined at 450 nm (reference filter, 620
nm); analysis was carried out as described for adhe-
sion molecule quantification, but the densities were
expressed as pg/mL. Hemoglobin concentrations
were used for correction of hemodilution effects.
The detection limits of the assays were given as 3, 2,
and 0.7 pg/mL, for TNFα, IL-6, and IL-8, respec-
tively. Normal values are 6 (range, 0-20), 4 (range,
1-8), and 8 (range, 0-47) pg/mL for TNFα, IL-6,
and IL-8, respectively.
Measurement of C3 and C3d complement
proteins. Plasma C3 and C3d complement protein
levels were measured through use of nephelometry
by means of a nephelometer Analyser II (Dade
Behring, Marburg, Germany) according to routine
procedures and expressed in milligrams per deciliters.
Hemoglobin concentrations were used for the cor-
rection of hemodilution effects on the concentrations
of these products. Each result was expressed as a
C3d/C3 ratio. Normal values are 0 to 1.4.
Statistical analysis
Each continuous variable is described as a mean ±
SEM. Data from the EAAA, OAAA, and control
groups were compared through use of analysis of vari-
ance with one between-subject factor (group) at three
levels and one repeated measures factor (time). The
model included the interaction between groups and
time factor, the interaction being considered signifi-
cant if the time pattern differed according to the
group. Multivariate tests concerning within-
subjects time effects and interaction between time and
group effect tests were based on F tests, with adjust-
ment of the degrees of freedom according to the
method proposed by Hyunh and Feldt.32 When a sta-
tistical mean time effect or an interaction between
time and group effect occurred, groups were studied
pairwise: analyses of variance were performed within
each group with one between-subject factor (group)
at two levels and one repeated measures factor (time).
When statistical significance occurred, each point was
then compared with the baseline preoperative value
through use of a multiple comparison procedure,
Bonferroni correction being taken into account.
Statistical analyses were performed by means of SPSS
statistical software (SPSS, Inc, Chicago, Ill).
RESULTS
Clinical findings. The surgical details are pre-
sented in Table II. There were no significant differ-
ences between groups with respect to aneurysm
diameter or the presence of intramural thrombus. In
contrast, aortic or femoral occlusion time and dura-
tion of surgery were significantly longer in patients
who underwent open AAA repair (P < .001 and P =
.012, respectively). Infusion volume and blood
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Carotid TEA (n = 3) P value: time course pattern between groups
Preop value Postop lowest value E vs O E vs TEA O vs TEA
1.16 (0.15) 0.87 (0.09)* .155 .523 .481
0.48 (0.13) 0.48 (0.14) .040 — —
0.12 (0.04) 0.06 (0.03)* .003 .461 .044
transfusion requirements were also significantly
higher in the OAAA group (P < .001 and P = .025,
respectively). Similarly, the systolic blood pressure
drop after the removal of aortic or femoral occlusion
was greater in the OAAA group than in the EAAA
group (26.60 vs 0.71 mm Hg; P = .011).
In the EAAA group, transfemoral placement of
the aortoiliac graft was successfully achieved in all
patients, with no open conversion. No intraoperative
complication was encountered in any patient.
Postoperative complications included one femoral
artery injury at the access site requiring surgical explo-
ration and patching of the vessel. Another patient had
bronchopneumonia on the third postoperative day;
intravenous antibiotic therapy was needed, and this
was followed by rapid recovery. No patient presented
with peripheral embolization or graft thrombosis. A
6-month follow-up period revealed no cases of endo-
graft migration, occlusion, or infection, but one per-
sistent minor distal perigraft leak had occurred.
In the OAAA group, all surgical procedures were
performed without intraoperative events. During
the postoperative period, two patients had bron-
chopneumonia on the third postoperative day and
were successfully treated with antibiotics. Each of
the other patients had an uneventful postoperative
course. A 6-month follow-up period revealed that
no graft occlusion or infection had occurred.
Laboratory findings. Significant global time
course effects were observed for CRP (P < .001) and
temperature (P = .002; Fig 1, A). Analysis of vari-
ance within each group showed nonsignificant time
course effects in the controls (P = .241 and P = .151
for CRP and temperature), whereas significant
effects were observed in the EAAA group (P < .001
and P = .035) and the OAAA group (P = .001 and
P = .048). Time course patterns differed between
the EAAA and OAAA groups for CRP (P = .032)
but not for temperature (P = .372).
Leukocyte and neutrophil counts showed signifi-
cant global time course effects (P < .001 and P < .001;
Fig 1, B). Analysis of variance within each group
showed significant time course effects in the EAAA (P
< .001 for both variables) and OAAA (P < .001 for
both variables) groups. Time course patterns differed
between these two groups: P = .002 and P = .009 (for
leukocyte and neutrophil counts, respectively). For
leukocyte count, a nonsignificant effect was observed
for the controls (P = .068). For neutrophil count, a
significant time course effect was noticed for the con-
trols (P = .019). Time course patterns differed
between the OAAA and control groups (P = .008) but
not between the EAAA and control groups (P = .507).
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Fig 2. Time course of peripheral T lymphocyte CD38
expression measured as MCF (nonlinear time scale). Each
result is expressed as mean (SEM). Continuous lines
between time points represent EAAA group, dotted lines
represent OAAA group, and broken lines represent control
group. P values after within-group tests comparing each
time point with baseline (preoperative) value are repre-
sented as follows: *P < .05, **P < .01.
Fig 3. Time course of soluble ICAM-1 and vWF mea-
sured as ng/mL and percents, respectively (nonlinear time
scale). Each result is expressed as mean (SEM).
Continuous lines between time points represent EAAA
group, dotted lines represent OAAA group, and broken
lines represent control group. P values after within-group
tests comparing each time point with baseline (preopera-
tive) value are represented as follows: *P < .05. 
Significant global time course effects were
recorded for lymphocyte, monocyte, and eosinophil
counts (P = .001, P < .001, and P < .001; Table III).
Regarding lymphocyte count, a significant time
course effect was observed in the controls (P =
.018). No differences in time course patterns were
noticed between groups. Regarding monocyte
count, analysis of variance within each group
showed a nonsignificant time course effect in the
controls (P = .721) and a significant difference in
time course patterns between the EAAA and OAAA
groups (P = .040). Regarding eosinophil count, a
significant time course effect was observed in the
controls (P = .042). No difference in time course
patterns was observed between the EAAA and con-
trol groups (P = .461), whereas significant differ-
ences were observed between the OAAA and con-
trol groups (P = .044) and between the EAAA and
OAAA groups (P = .003). 
As shown in Table IV, flow cytometric analysis of
peripheral T lymphocyte surface activation markers
such as CD69, CD40L, and CD25 (IL-2R) revealed
no perioperative fluctuations in any group.
Moreover, preliminary experiments failed to identify
variations in CD11a expression (data not shown).
Similarly, surface expression of peripheral monocyte
activation markers such as CD40 (data not shown)
and of adhesion molecules such as CD11b (data not
shown) and CD54 (ICAM-1; Table IV) displayed
no upregulation of their expression levels.
Interestingly, however, peripheral T lymphocyte
CD38 expression demonstrated a significant global
time course effect (P = .001; Fig 2). Analysis of vari-
ance within each group showed a significant time
course effect in the OAAA group (P = .001), where-
as it failed to reach significance in the EAAA group
(P = .082) and in the control group (P = .076).
Furthermore, sICAM-1 and vWF levels dis-
played significant global time course effects (P <
.001; Fig 3). For sICAM-1, analysis of variance
within each group showed significant time course
effects in the EAAA and OAAA groups (P = .003
and P = .001), whereas it failed to reach significance
in the control group (P = .745). Time course pat-
terns did not differ between the EAAA and OAAA
groups (P = .193). For vWF, significant time course
effects were demonstrated in the three groups (P =
.018, P = .007, and P = .027), with no difference in
time course patterns observed (P = .772). Other sol-
uble adhesion molecules, such as sVCAM-1, sE-
selectin, and sP-selectin, did not appear to vary with
any type of AAA repair (Table IV).
Although tendencies toward high TNFα and IL-
8 levels were noticed in the EAAA group (Fig 4, A),
global time course effects failed to reach statistical
significance (P = .543 and P = .080), as did time
course patterns between groups (P = .639 and P =
.066). In contrast, levels of IL-6 showed a signifi-
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Fig 4. A, Time course of TNFα and IL-8 responses mea-
sured as pg/mL (nonlinear time scale). Each result is
expressed as mean (SEM). Continuous lines between time
points represent EAAA group, dotted lines represent
OAAA group, and broken lines represent control group. B,
Time course of IL-6 response measured as pg/mL (non-
linear time scale). Results are expressed as mean (SEM).
Continuous lines between time points represent EAAA
group, dotted lines represent OAAA group, and broken
lines represent control group. P values after within-group
tests comparing each time point with baseline (preopera-
tive) value are represented as follows: *P < .05.
A
B
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cant global time course effect (P = .013) (Fig 4, B).
Analysis of variance within each group showed sig-
nificant time course effects for all groups (P = .058,
P < .001, and P = .004). Time course patterns did
not differ between the EAAA and OAAA groups (P
= .840), whereas they did between the EAAA group
or the OAAA group and the controls (P = .029 and
P = .051).
Last, the C3d/C3 ratio showed a significant
global time course effect (P = .002; Fig 5). Analysis
of variance within each group showed a nonsignifi-
cant time course effect in the controls (P = .080),
whereas significant effects were observed in the
EAAA and OAAA groups (P = .013 and P = .009).
This release of complement products appeared to be
significantly earlier and higher in the OAAA group
(P < .001).
DISCUSSION
The current study indicated that both endovas-
cular and conventional AAA repair induced signifi-
cant early acute systemic inflammatory responses
involving acute phase reaction (CRP synthesis, fever,
and leukocytosis), soluble ICAM-1 shedding, IL-6
(without TNFα or IL-8) release, and liberation of
complement products. Our data showed that
sICAM-1 and IL-6 levels followed similar time
course patterns in both groups, suggesting that
there were few differences between the procedures
with respect to circulating cell adhesion molecule
and cytokine release. In contrast, our findings
revealed that endovascular repair produced a lower
acute phase response, a reduced complement activa-
tion, and no peripheral T lymphocyte activation in
comparison with open surgery.
Regarding circulating cell adhesion molecules,
our data failed to exhibit modifications in soluble lev-
els of VCAM-1, E-selectin, or P-selectin in any
group. In addition, vWF levels displayed significant
but similar elevations in all groups, including the
controls, suggesting that the observed vWF release
could be related to inflammatory events caused by
the surgical insult itself. ICAM-1, an Ig-like protein
expressed by several cell types (including leukocytes
and endothelial cells), is considered to play a central
role in the migration of activated leukocytes to sites
of inflammation by promoting leukocyte firm 
attachment to endothelium and transendothelial
migration. ICAM-1 cell surface expression and shed-
ding into soluble plasma forms are induced and 
modulated by inflammatory mediators such as cyto-
kines during inflammatory responses. Interestingly,
patients in both the EAAA group and the OAAA
group (but not in the control group) showed signif-
icant postoperative elevations of sICAM-1 in our
series. This can be considered as a marker for the
presence of inflammation and suggests involvement
of leukocyte-endothelium interactions in the inflam-
matory events occurring in both procedures.
Further interpretation of sICAM-1 data appears
to be difficult, inasmuch as several cell types may be
responsible for the levels detected. Moreover, our
data are in agreement with previous studies indicat-
ing either an elevation of ICAM-1 after convention-
al AAA repair5,33 or an upregulation of ICAM-1 on
endothelial cells exposed to Dacron prostheses.34
Regarding cytokine release, a review of the litera-
ture reveals that the question of whether a TNFα
response could occur after aortic surgery remains a
matter of controversy. Although some studies showed
high TNFα levels—sometimes correlated with poor
outcome5—after conventional AAA repair,5,24,35-37
Table IV. Circulating cell adhesion molecules and surface expression of selected T lymphocyte and mono-
cyte activation and adhesion markers
AAA repair P value
Endovascular (n = 7) Conventional (n = 5) Global time Time course pattern 
Preop value Postop peak value Preop value Postop peak value course effect between groups
CD69 (MCF) 2.01 (0.15) 2.38 (0.36) 1.98 (0.19) 2.43 (0.33) .558 .809
CD40L (MCF) 3.09 (1.03) 5.28 (1.64) 2.75 (0.78) 4.69 (1.09) .313 .884
CD25 (MCF) 2.29 (0.13) 2.55 (0.28) 2.23 (0.14) 2.74 (0.21) .596 .641
CD54 (MCF) 16.81 (2.40) 17.53 (2.69) 10.99 (2.00) 16.84 (4.01) .060 .672
sVCAM-1 (ng/mL) 378.00 (28.10) 1370.15 (879.27) 400.63 (62.83) 915.06 (376.09) .381 .464
sE-Selectin (ng/mL) 32.99 (4.63) 63.39 (29.37) 34.52 (13.85) 34.51 (5.59) .528 .511
sP-Selectin (ng/mL) 88.92 (10.83) 178.71 (61.52) 80.26 (20.59) 165.27 (43.99) .204 .654
Each variable is expressed as mean value (SEM).
others did not.3,4,25-28,38-40 Furthermore, studies
examining both EAAA and OAAA either described a
more pronounced TNFα release in OAAA24 or failed
to identify liberation of TNFα in any group.25 In con-
trast to these data, recent observations26-28 described
a specifically endoluminal-related TNFα response
associated with a clinically relevant drop in blood
pressure. The same authors showed that TNFα pro-
duction could arise as a consequence of WBC activa-
tion triggered by IL-6 release from the aneurysmal
thrombus during manipulations related to insertion
of the device.29 Our data are not in line with these
previous findings; although a tendency toward early
acute TNFα production was noticed in EAAA, it
failed to reach statistical significance. In addition, no
TNFα production was noted in OAAA.
Numerous reports have described IL-6 and/or
IL-8 release after OAAA,3,5,26,35-41 sometimes
establishing that a persistent rise in IL-6 levels in the
postoperative period may be a valuable predictor of
serious complications.5,36 Only a few studies have
investigated these cytokines after EAAA. Some
reports have shown either that OAAA induced a
higher IL-6 response,25,26 thereby suggesting that
IL-6 might reflect tissue damage caused by reperfu-
sion injury or surgical trauma, or that EAAA failed
to induce IL-8 release.26 Actually, our data also
failed to demonstrate significant IL-8 release in any
procedure. Otherwise, our findings revealed high
IL-6 levels in all groups, with a significantly higher
response in the EAAA and OAAA groups than in the
control group. Moreover, IL-6 release patterns were
comparable in the EAAA and OAAA groups, sug-
gesting similar participation of IL-6 in the modula-
tion of the inflammatory events occurring in both
procedures. In addition, one may suppose that the
production of IL-6 in OAAA may be linked to the
extent of either tissue damage (caused by ischemia-
reperfusion injury and surgical insult) or blood
transfusion, whereas IL-6 release in EAAA may be
caused by manipulations into the aneurysmal throm-
bus, as has been suggested.26-29
Regarding lymphocyte activation, we in fact
observed a clear upregulation of peripheral T lym-
phocyte CD38 expression after OAAA; this has not
been described previously. Human lymphocyte
CD38 glycoprotein has been involved42-44 in sever-
al activities, including peripheral blood mononuclear
cell activation and proliferation (signal transduction
for the transcription of various cytokines, such as IL-
6 and TNFα) and mediation of lymphocyte migra-
tion and adhesion (rolling) to endothelium.
Therefore, our results indicate that CD38-mediated
T lymphocyte activation and adhesion might be
involved in one of the distinctive and specific aspects
of the inflammatory response related to OAAA. Our
findings corroborate and extend previous observa-
tions35,41 suggesting T lymphocyte activation after
OAAA (as demonstrated by postoperative soluble
IL-2 receptor release), and they indicate a need for
further investigations, including studies of T cell
functional properties with determination of type 1
or 2 cytokine secretion profiles.
Otherwise, our data failed to describe upregula-
tion of surface expression of peripheral leukocyte
adhesion molecules (such as CD11a/CD18 and
CD11b/CD18 β2 integrins) or activation markers
(such as CD69, CD25, and the CD40-CD154 path-
way) in any group. Our results are not in line with
previous reports showing upregulation of leukocyte
adhesion molecules after either conventional4,33 or
endovascular27,28 surgery (particularly on healthy
volunteers’ WBCs exposed to patients’ plasma28) or
after in vitro contact with biomaterials.45 In our
study, the absence of response for these surface mol-
ecules might theoretically be explained by the limit-
ed sensitivities of the techniques used or by the fact
that some activated lymphocytes and monocytes may
be adherent or marginated to the inflamed endothe-
lium or to the biomaterial itself. Concomitant obser-
vations of decreases in lymphocyte and monocyte
counts in our patients might constitute indirect evi-
dence for this phenomenon. In fact, other clinical
studies have shown decreased lymphopenia35 and
monopenia26-28 after OAAA and/or EAAA and have
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Fig 5. Time course of plasma C3 and C3d complement
protein concentrations measured as C3d/C3 ratio (non-
linear time scale). Each result is expressed as mean (SEM).
Continuous lines between time points represent EAAA
group, dotted lines represent OAAA group, and broken
lines represent control group. P values after within-group
tests comparing each time point with baseline (preopera-
tive) value are represented as follows: *P < .05.
therefore evoked this hypothesis. Several in vitro
experiments46-48 have also demonstrated leukocyte
adhesion to vascular biomaterials.
Regarding complement cascade, our data
demonstrated significant complement activation
after both AAA procedures, as evidenced by eleva-
tions of C3d/C3 ratios. Furthermore, the response
appeared to be significantly lower in EAAA. Our
results are in accord with previous reports concern-
ing OAAA, either alone3,35,38,49 or in comparison
with EAAA.26 In addition, several in vitro studies
have shown that some biomaterials are able to
induce complement activation.48,50 Moreover, Åvall
et al51 have reported that blood transfusion may also
lead to complement activation.
In view of these findings and with the main lim-
itations of our study (which are related to the small
number of patients) being taken into account, our
data showed that there were no large differences
between the AAA repair methods with respect to
soluble cell adhesion molecule and cytokine release.
In contrast, EAAA induced a reduced response in
terms of acute phase reaction, T cell activation, and
liberation of complement proteins. One may postu-
late that several pathophysiologic mechanisms could
theoretically explain these limited inflammatory
events. First, the limited extent of tissue damage,
blood transfusion, and ischemia-reperfusion injury
could play a major role. Second, when it is consid-
ered that inflammation may partly be triggered by
the biomaterial itself, the fact that the biomaterial
covering our endografts (polycarbonate-urethane) is
different from that (Dacron) which lined the vascu-
lar grafts used in our series and the endografts used
in other studies (particularly those26-28 showing a
specific TNFα release after endovascular repair)
could also be involved in the distinctive features of
the observed inflammatory responses. One may
therefore assume that polycarbonate-urethane might
be more inert and less immunogenic than Dacron.
Wider clinical studies and additional in vitro experi-
ments are warranted to assess this hypothesis.
On the other hand, one may suppose that
inflammation induced by EAAA might be due to tis-
sue damage (although highly limited), cell interac-
tions with the biomaterial lining the endograft, or
manipulations with introducers and catheters into
the aneurysm and its intramural thrombus. These
maneuvers may indeed lead to either release of cer-
tain cytokines (such as IL-6) from the thrombus29
or direct endothelial damage, both of which are con-
sequently able to promote inflammatory events.
This enables us to further support the concept29 that
restricted manipulations within the aneurysm and its
intramural thrombus during insertion of the device
may have the ability to minimize biologic responses
induced by EAAA, which might contribute to an
improvement in the management of the condition.
CONCLUSIONS
In conclusion, taking into consideration the
main limitations of our work, which are related to
the small sample size, we found that both EAAA and
OAAA induced significant early acute inflammatory
responses involving several components of the
inflammatory cascade, such as acute phase reaction,
shedding of adhesion molecules, IL-6 release, and
liberation of complement products. Our findings
showed that soluble ICAM-1 levels and IL-6 pro-
duction followed similar time course patterns, sug-
gesting that there were no large differences between
the procedures in terms of circulating cell adhesion
molecule and cytokine release. Furthermore, acute
phase response and complement cascade activation
were reduced by EAAA in comparison with OAAA.
Moreover, OAAA produced peripheral T lympho-
cyte activation involving the CD38 pathway. These
observations might therefore support the concept
that endoluminal AAA repair represents an interest-
ing alternative to open surgery. Larger studies are
needed to confirm this point and to identify the
pathophysiologic mechanisms underlying the
observed inflammatory events.
We are greatly indebted to S. Cognet for technical
support in the measurement of complement proteins and
to J. Stokes for editorial assistance.
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